Cash Pay to Drive Major Share of Wegovy Sales, Says Novo Nordisk CFO

Novo Nordisk Faces Multiple Challenges Amid Earnings Miss and Leadership Changes

Novo Nordisk, a leading pharmaceutical company known for its blockbuster GLP-1 drugs Ozempic and Wegovy, recently reported an earnings miss, which caused its stock to drop 4% in early trading. This decline adds to the pressure on the company following a surprising management shake-up earlier this year and a sharp reduction in guidance, despite continued growth in sales of its GLP-1 medications.

The stock has lost more than 46% of its value year to date, reflecting growing concerns among investors. The leadership change, which saw the ousting of CEO Lars Jørgensen and the appointment of Mike Doustdar as the new international head, was described by CFO Karsten Munk Knudsen as a surprise. He noted that while such changes are not uncommon in other companies under pressure, it was unexpected within the context of Novo Nordisk’s operations.

US Market Challenges and Compounding Competition

One of the key challenges facing Novo Nordisk is its struggle in the US market, where it has lost its initial advantage to competitor Eli Lilly. Executives have pointed to the compounding market as a significant factor. This market allows copycat versions of GLP-1 drugs to be sold under special circumstances, even after the FDA addressed a shortage of GLP-1s that previously allowed these products to circulate freely.

Knudsen mentioned that the compounding market accounts for about one-third of current GLP-1 prescriptions in the US. This competition has put additional pressure on Novo Nordisk, especially as it faces regulatory scrutiny from the Trump administration. The company was among 17 firms that received letters demanding lower prices for both existing and new products.

Pricing Strategies and Cash Market Potential

Despite these challenges, Novo Nordisk maintains that its pricing strategy already aligns with affordability goals. Knudsen emphasized that the company’s GLP-1 pricing is relatively low, though he did not disclose specific figures. Outgoing CEO Lars Jørgensen also highlighted that prices for Medicaid programs are already lower than those in Europe, although these details remain confidential.

The Trump administration's push for lower drug prices has raised questions about the feasibility of such strategies. Craig Garthwaite, a professor at Northwestern University’s Kellogg School of Management, questioned the viability of relying on out-of-pocket payments for brand-name drugs. His analysis suggested that many consumers may not be willing to pay cash for these medications, even if the price is lower than the list price.

However, Knudsen remains optimistic about the potential of the cash market. He pointed out that 10% of Wegovy patients in the US are currently paying cash through NovoCare, the company’s direct-to-consumer channel. He believes this percentage will grow significantly in the future, as the overall cash market for GLP-1 drugs is already above 10%.

Compounding Market Insights and Competitive Pressure

The compounding market, where customers pay cash and represent a third of the Wegovy market, offers valuable insights into the potential of the cash sector. However, the prices for these copycat drugs are much lower than the $499 per month charged by NovoCare. For example, Hims and Hers, a company that Novo recently severed ties with over its refusal to stop selling compounded semaglutide, advertises prices as low as $199 per month for a 12-month plan.

As Novo Nordisk navigates these challenges, the company continues to focus on its long-term strategy and the evolving landscape of the pharmaceutical industry. The coming months will be critical in determining how effectively it can maintain its position in the market amid intense competition and regulatory pressures.